Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jeff Evanson Insider Profile
11 Followers
Jeff Evanson, CCO at Outlook Therapeutics, holds 808.46K shares in Outlook Therapeutics (Ticker: OTLK). Most recently, Jeff Evanson Bought $62,484 shares of Outlook Therapeutics on Mar 11, 2024 for an estimated value of 26.24K.
Profitable Transactions
4 out of 6 Profitable Transactions
Average Return
+28.40%
Average return per transaction
Time Frame
Compare to
Insider Roles
CCO
Roles that Jeff Evanson holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jan 19, 2023 - Jan 19, 2024
Return:+70.90%
The most profitable trade made by Jeff Evanson
Jeff Evanson's Trading History
List of latest transactions for each holding click on a transaction to see Jeff Evanson's performance on stock
You May Also Like
Jeff Evanson insider profile FAQ
What is the percentage of profitable transactions made by Jeff Evanson?
The percentage of profitable transactions made by Jeff Evanson is 67%.
What is the average return per transaction made by Jeff Evanson?
The average return per transaction made by Jeff Evanson is 28.40%.
What stocks does Jeff Evanson hold?
Jeff Evanson holds: OTLK stocks.
What was Jeff Evanson’s latest transaction?
Jeff Evanson latest transaction was an Informative Buy of $26.24K.
What was Jeff Evanson's most profitable transaction?
Jeff Evanson’s most profitable transaction was an Informative Sell of OTLK stock on January 19, 2023. The return on the trade was 70.90%.
What is Jeff Evanson's role in Outlook Therapeutics?
Jeff Evanson's role in Outlook Therapeutics is CCO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.